FriSCy guidance for use of denosumab to reduce risk of re-fracture: MHRA Drug safety alert vol 6, Issue 3 October 2012 V1[removed]Why do I need to read this? There has been a recent MHRA drug safety alert (alert vol 6 - Amgen - Document - PDFSEARCH.IO

First Page	Meta Content
	FriSCy guidance for use of denosumab to reduce risk of re-fracture: MHRA Drug safety alert vol 6, Issue 3 October 2012 V1[removed]Why do I need to read this? There has been a recent MHRA drug safety alert (alert vol 6 Add to Reading List Document Date: 2013-05-14 12:09:19 Open Document File Size: 211,56 KB Share Result on Facebook Company Moderate Severe 30 / / Event Product Issues / / IndustryTerm function / / MedicalCondition chronic kidney disease / kidney disease / / MedicalTreatment dialysis / / Organization MHRA / / Position physician / treating physician / secondary care specialist / / Product vitamin D / renal function / / ProvinceOrState Oregon / / Technology dialysis / / SocialTag Biology Matter Amgen Denosumab Kidney diseases Hypocalcaemia Renal function Hypercalcaemia Chronic kidney disease Medicine

FriSCy guidance for use of denosumab to reduce risk of re-fracture: MHRA Drug safety alert vol 6, Issue 3 October 2012 V1[removed]Why do I need to read this? There has been a recent MHRA drug safety alert (alert vol 6Add to Reading List